 CAMBRIDGE, Mass., Jan. 04, 2022 GLOBE NEWSWIRE -- Vor Biopharma Nasdaq: VOR, a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences: 